APG-1252

DRUG6 trials

Sponsors

Ascentage Pharma Group Inc.

Conditions

EGFR Positive Non-small Cell Lung CancerMyelofibrosisNHL, AdultSmall Cell Lung CancerSmall Cell Lung Cancer and Other Solid TumorsSolid Tumor

Phase 1

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

CompletedNCT03080311

Ascentage Pharma Group Inc.Small Cell Lung Cancer, Solid Tumor

Start: 2017-02-12End: 2020-07-17Updated: 2022-07-12

APG-1252 in Patients With SCLC or Advanced Solid Tumors

TerminatedNCT03387332

Ascentage Pharma Group Inc.Small Cell Lung Cancer and Other Solid Tumors

Start: 2017-12-01End: 2021-04-15Updated: 2021-08-27

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active, not recruitingNCT04001777

Ascentage Pharma Group Inc.EGFR Positive Non-small Cell Lung Cancer

Start: 2019-07-04End: 2026-06-30Target: 80Updated: 2025-10-01

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

TerminatedNCT04210037

Ascentage Pharma Group Inc.Small Cell Lung Cancer

Start: 2020-08-20End: 2022-05-15Updated: 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

WithdrawnNCT04354727

Ascentage Pharma Group Inc.Myelofibrosis

Start: 2020-12-15End: 2023-06-15Updated: 2022-07-12

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

RecruitingNCT05186012

Ascentage Pharma Group Inc.NHL, Adult

Start: 2022-06-14End: 2026-03-31Target: 51Updated: 2024-01-23

Related Papers

First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).

Journal of Clinical Oncology2022-06-015 citations

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with <i>EGFR</i>-mutant non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-011 citations

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Blood2021-11-054 citations

Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).

Journal of Clinical Oncology2021-05-205 citations

Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Blood2020-11-044 citations

First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.

Journal of Clinical Oncology2020-05-2018 citations

Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models

Cancer Research2018-07-011 citations

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

Journal of Clinical Oncology2018-05-209 citations